Advaxis Licenses Antigen Delivery Technology to Sellas for Cancer Immunotherapy – Genetic Engineering & Biotechnology News (press release)
Xconomy |
Advaxis Licenses Antigen Delivery Technology to Sellas for Cancer Immunotherapy
Genetic Engineering & Biotechnology News (press release) Advaxis has licensed its proprietary Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358 million for Advaxis, the companies said today. Sellas plans to develop a cancer immunotherapy … Advaxis Inks Deal with Sellas to Develop New Cancer ImmunotherapyXconomy Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting ImmunotherapyEconoTimes Advaxis pens backloaded $358M cancer delivery tech dealFierceBiotech |
Medscape |
First Look at Combo With Immunotherapy in Untreated mRCC
Medscape ORLANDO, Florida – Use of the immunotherapy atezolizumab (Tecentriq, Roche) in combination with bevacizumab (Avastin, Roche) nearly doubled progression-free survival (PFS) compared with sunitinib (Sutent, Pfizer) as a first-line treatment in patients … |
|
CureDuchenne Ventures Commits $5M to Startup With CRISPR-Based DMD Therapy
Genetic Engineering & Biotechnology News The venture philanthropy arm of the nonprofit CureDuchenne has committed $5 million in seed financing toward a startup focused on using gene editing technologies such as CRISPR/Cas9 to permanently correct most mutations causing Duchenne muscular … |
Xconomy |
Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy
Xconomy Advaxis and Sellas Life Sciences Group, two companies that have pursued different ways of prompting the body’s immune system to fight cancer, are now hoping that combining their efforts will lead to a more precise treatment. The agreement between the … Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting ImmunotherapyEconoTimes |
|
Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM …
GlobeNewswire (press release) Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S. … |
|
-exploring-what-stem–cells-can-do-now-and-in-the-future
thepaper24-7.com Last week I hope I answered the first part of our reader’s question about how DNA can be used to treat inherited conditions. This week I want to focus on stem cells – what they are, where they come from, how they might be used to treat disease and … Stem Cell Therapy Market to Receive overwhelming hike in Revenues by 2020Satellite PR News (press release) |
|
-exploring-what-stem–cells-can-do-now-and-in-the-future
thepaper24-7.com Last week I hope I answered the first part of our reader’s question about how DNA can be used to treat inherited conditions. This week I want to focus on stem cells – what they are, where they come from, how they might be used to treat disease and … Mesenchymal Stem Cells Market Pegged for Robust Expansion by 2020Medgadget (blog) Stem Cell Therapy Market to Receive overwhelming hike in Revenues by 2020Satellite PR News (press release) |